Cencora, Inc.

Cencora (NYSE: COR) executives highlighted the company's specialty pharmaceutical positioning, medical specialty organization strategy and capital-allocation priorities during an investor conference discussion, while reaffirming the durability of its relationship with Walgreens. Chief Executive Officer Bob Mauch said Cencora's growth is being supported by pharmaceutical innovation, demographic trends and the company's long-standing investments in specialty distribution and

Cencora NYSE: COR executives highlighted the company's specialty pharmaceutical positioning, medical specialty organization strategy and capital-allocation priorities during an investor conference discussion, while reaffirming the durability of its relationship with Walgreens.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Corient Private Wealth LP lifted its holdings in Cencora, Inc. (NYSE: COR) by 102.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 37,601 shares of the company's stock after buying an additional 19,068 shares during the period. Corient Private Wealth LP's